文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性换用阿柏西普8 mg的真实世界12个月结果:654眼随访

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes.
PubMed 文献 · Retina · 2026-05-26

本研究回顾性评估了654只既往接受过抗VEGF治疗并处于平台期的nAMD眼,系统性换用阿柏西普8 mg后12个月的结局。换用后干性黄斑比例从55%升至3个月76%、6个月73%、12个月69%,平均治疗间隔从6.0周延长至7.8周,但BCVA从68.5 letters轻微下降至67.3 letters。结论认为换药改善了解剖学结局并减少了短间隔治疗比例,但视力轻微下降需长期随访。

要点

  • 换用阿柏西普8 mg后干性黄斑比例从55%升至3个月76%、6个月73%、12个月69%。
  • 3-5周短间隔治疗眼比例从46%降至12个月18%,9-12周间隔眼从11%升至34%。
  • 平均治疗间隔从6.0周延长至7.8周,但BCVA从68.5 letters轻微下降至67.3 letters。

核心结论

  • 换用阿柏西普8 mg改善了nAMD眼的解剖学结局并减少了短间隔治疗比例,但BCVA出现轻微下降,需长期随访。

研究设计与样本

  • 回顾性研究,纳入654只来自567例患者的既往接受过抗VEGF治疗(每眼平均34.5次注射)且处于平台期的nAMD眼。
  • 在换药时及换药后3、6、12个月评估治疗间隔、BCVA、CRT及IRF/SRF数据。

主要发现

  • 干性黄斑比例从换药时55%升至3个月76%(P<0.001)、6个月73%(P<0.001)、12个月69%(P<0.05)。
  • 3-5周间隔治疗眼从46%降至12个月18%(P<0.001),9-12周间隔眼从11%升至34%(P<0.001)。
  • 平均治疗间隔从6.0(2.1)周延长至7.8(2.4)周(P<0.001);换药时干性黄斑眼延长2.6(1.8)周(P<0.001)。
  • 平均CRT从234.7(49.7)µm降至223.5(46.7)µm(P<0.001)。
  • 总体BCVA从68.5(12.2)ETDRS letters降至67.3(13.9)letters;换药时干性黄斑眼从68.5(12.3)降至66.6(14.3)letters(P<0.001)。

关键数值与推荐

  • 平台期定义为既往抗VEGF注射≥10次。
  • 平均年龄82.4(7.4)岁,换药前每眼平均注射34.5(21.5)次。

临床怎么用

  • 对既往抗VEGF治疗处于平台期的nAMD眼,换用阿柏西普8 mg可提高干性黄斑比例并延长治疗间隔。
  • 换药后需监测BCVA,因本研究观察到视力轻微下降。

局限性

  • 回顾性设计,仅纳入平台期且既往注射≥10次的眼睛,结果外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 12-month outcomes following systematic switch to aflibercept 8 mg in previously treated eyes with age-related neovascular macular degeneration (nAMD). METHODS: Eyes in a plateau phase (≥10 prior anti-VEGF injections) that were switched to aflibercept 8 mg were retrospectively evaluated. Treatment intervals, best corrected visual acuity (BCVA), central retinal thickness (CRT), and data on intraretinal fluid (IRF) or subretinal fluid (IRF) were assessed at switch and after 3, 6, and 12 months. RESULTS: In total, 654 eyes from 567 patients were included (mean [SD] age 82.4 [7.4], 34.5 [21.5] injections per eye before switch). The proportion of eyes with dry maculae increased from 55% at switch to 76% at 3 months (P<0.001), 73% at 6 months (P<0.001), and 69% at 12 months (P<0.05). Eyes treated at 3-5-week intervals declined from 46% to 18% at 12 months (P<0.001). Eyes on 9-12-week intervals increased from 11% to 34% (P<0.001). The mean treatment interval increased from 6.0 (2.1) to 7.8 (2.4) weeks (P<0.001). Eyes with dry maculae at switch were extended by 2.6 (1.8) weeks (P<0.001). The mean CRT decreased from 234.7 (49.7) to 223.5 (46.7) µm (P<0.001). BCVA declined from 68.5 (12.2) to 67.3 (13.9) ETDRS letters in the overall cohort, and from 68.5 (12.3) to 66.6 (14.3) ETDRS letters in eyes with a dry macula at switch (P < 0.001). CONCLUSION: Switching to aflibercept 8 mg improved anatomical outcomes and reduced the proportion of eyes on short intervals. A slight decline in BCVA was observed, warranting long-term follow-up.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lee C, Karunainathan MG, Zohalinejad KD, et al. Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes. Retina. 2026. PMID: 42190237. doi:10.1097/IAE.0000000000004888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。